-
HFPO-DA, CK2, and Ischemic Stroke Injury
2026-09-02
A 2026 rat study identifies HFPO-DA, or GenX, as an environmental factor that worsens ischemia–reperfusion brain injury and implicates the CSNK2A1/GSK3B/NF-κB axis in this effect. By combining exposure modeling, molecular docking, CETSA, CSNK2A1 knockdown, and pharmacological rescue with CX-4945, the work connects a PFAS substitute to microglia-associated neuroinflammation.
-
I-BET151 (GSK1210151A) Research Workflow
2026-09-02
Build a practical BET-inhibition workflow around I-BET151 (GSK1210151A) for cancer biology, combining transcriptional perturbation with viability, apoptosis, and cell-cycle readouts. The guide also shows how the compound can be used as an exploratory chromatin-perturbation arm in organoid studies inspired by recent PDX1 and m6A research.
-
SNS-032 (BMS-387032): Reliable Cell Assays
2026-09-01
This scenario-based guide shows how SNS-032 (BMS-387032), SKU A1980, can support reproducible cell viability, proliferation, cytotoxicity, and mechanistic assays. It connects biochemical potency, RNA polymerase II phosphorylation, formulation, storage, and cross-domain evidence to practical laboratory decisions.
-
T0070907 as a Causal Probe of PPARγ Signaling
2026-09-01
T0070907 is a high-affinity PPARγ antagonist for separating receptor-dependent transcription from broader pathway effects. This article translates RXRα/PPARγ/NEDD4 findings in atherosclerotic foam cells into a practical assay strategy for inflammation, adipogenesis, and cell-cycle research.
-
Nocodazole: Microtubule Polymerization Inhibitor
2026-08-31
Nocodazole is a reversible microtubule polymerization inhibitor that binds β-tubulin and perturbs spindle formation, trafficking, and microtubule dynamics. Its research value is strongest in controlled cell-cycle and cytoskeletal assays, while pathogen-entry and therapeutic interpretations require condition-specific controls.
-
Simvastatin (Zocor): Applied Research Workflows
2026-08-31
Build reproducible lipid-metabolism and hepatic cancer assays with Simvastatin (Zocor), from solvent handling and dose selection to orthogonal apoptosis and cell-cycle validation. A stress-biology reference study adds a practical framework for separating translation defects, proteasomal loss, and cell-fitness changes without implying that simvastatin is an ALS treatment.
-
(Z)-4-Hydroxytamoxifen: Assay Logic
2026-08-30
(Z)-4-Hydroxytamoxifen is a high-affinity ER modulator for dissecting estrogen-dependent signaling. This guide connects its receptor pharmacology with a ferroptosis-focused osteoarthritis study to show how orthogonal controls improve assay interpretation.
-
Palbociclib (PD0332991) Assay Design
2026-08-29
Palbociclib and PD0332991 are usually described as selective CDK4/6 inhibitors, but their greatest experimental value may be as timed cell-cycle perturbagens. This guide connects G0/G1 arrest and Rb signaling with ERCC1–p53 DNA-repair biology to improve assay interpretation without overstating an untested drug interaction.
-
Cyclopamine Workflows for Hh Research
2026-08-28
Cyclopamine is a practical Hedgehog signaling inhibitor for connecting Smoothened biology with cancer-cell phenotypes and developmental tissue responses. This guide provides assay-ready dosing logic, comparative model selection, and troubleshooting for apoptosis, proliferation, and genital-tubercle explant studies.
-
Bufalin–CRISPR Nanomedicine for Colorectal Cancer
2026-08-28
The reference study develops a calcium lactate nanoparticle that co-delivers bufalin and a CD47-targeting CRISPR/Cas9 ribonucleoprotein to coordinate tumor-cell death with macrophage-mediated immunity. Its central finding is that pyroptosis, apoptosis, M1 macrophage reprogramming, and removal of CD47 antiphagocytic signaling can be integrated into one preclinical strategy for local tumor control and systemic antitumor activity.
-
Cyclopamine: Hedgehog Signaling Workflows
2026-08-27
Cyclopamine is a practical Hedgehog signaling inhibitor for connecting Smoothened biology with cancer-cell phenotypes, developmental mechanisms, and sensory assays. This workflow-focused guide covers dosing, controls, cross-model interpretation, and troubleshooting beyond simple pathway inhibition.
-
THZ1 Workflows for CDK7 and T-ALL Research
2026-08-27
THZ1 combines nanomolar CDK7 potency with covalent target engagement, making it useful for linking transcriptional disruption to cancer-cell phenotypes. This practical guide shows how to build dose–response, transcription, and apoptosis workflows while avoiding common errors caused by solvent handling, timing, and overinterpretation of IC50 values.
-
IWR-1-endo for Reliable Cell Assays
2026-08-26
A scenario-driven guide to using IWR-1-endo (SKU B2306) in cell viability, proliferation, and cytotoxicity workflows. It connects Wnt/β-catenin mechanism with practical stock preparation, assay controls, interpretation, and supplier-selection criteria.
-
MK-8745 Aurora A Inhibitor: Assay Guide
2026-08-26
A practical, scenario-based guide to using MK-8745, Aurora A inhibitor, potent and selective (SKU A8807) in viability, proliferation, cell-cycle, and apoptosis assays. It connects formulation, dosing, model selection, and data interpretation with Aurora A biology and recent cancer research.
-
Y-27632 and the Adhesion Barrier in Chimerism
2026-08-25
A translational framework for using Y-27632 dihydrochloride as a mechanistic ROCK inhibitor control when studying stem cell survival, cytoskeletal organization, and interspecies cell adhesion.